Ionis Pharmaceuticals Has Completed Enrollment In The Phase 3 CARDIO-TTRansform Study Of Eplontersen In Patients With Transthyretin-mediated Amyloid Cardiomyopathy; The Study Enrolled Over 1,400 Patients
Portfolio Pulse from Benzinga Newsdesk
Ionis Pharmaceuticals has completed enrollment in the Phase 3 CARDIO-TTRansform study of Eplontersen in patients with Transthyretin-mediated Amyloid Cardiomyopathy. The study enrolled over 1,400 patients.
July 31, 2023 | 11:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ionis Pharmaceuticals has completed enrollment for its Phase 3 study of Eplontersen. This could potentially lead to positive results and subsequent FDA approval, which would be beneficial for the company's stock.
Completion of enrollment for a Phase 3 study is a significant milestone for any pharmaceutical company. It means that the company is one step closer to potentially having a new drug approved by the FDA. If the results of the study are positive, it could lead to increased revenues for the company, which would likely have a positive impact on the company's stock price.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100